Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States".
R Brett McQueenMelanie D WhittingtonRick H ChapmanVarun M KumarJonathan D CampbellPublished in: PharmacoEconomics (2019)
Keyphrases